Skip to main content
. 2016 Mar 4;7(14):18694–18704. doi: 10.18632/oncotarget.7909

Figure 5. MEDICA-induced ROS production in HT29 cells.

Figure 5

(A) MEDICA-induced ROS production as verified by DCFDA fluorescence and decrease in GSH/GSSG ratio. Mean ± SE. *Significant as compared to respective control. #Significant as compared to the respective MEDICA concentrations. (B) MEDICA-induced mitochondrial ROS production as verified by mitoSOX and succinate-dependent Amplex Red fluorescence. Mean ± SD. *Significant as compared to control. (C) Suppression of PP2A activity by MEDICA-induced ROS. Mean ± SE. *Significant as compared to respective control. #Significant as compared to respective control. (D–F) Activation of Erk downstream targets (D), increase in p21 (E), and suppression of EGF- and IL-6-induced STAT3 and Akt (F) by MEDICA are abrogated by NAC. Representative blots. (G) Suppression of cell growth (48 h) by MEDICA is abrogated by NAC. Mean ± SD. *Significant as compared to growth in NAC absence. (H) Suppression of clonogenic growth by MEDICA is abrogated by PEG-SOD (100 u/ml). Mean ± SD. *Significant as compared to respective control.